US2023372297A1PendingUtilityA1

Medicaments for the treatment or prevention of fibrotic diseases

85
Assignee: BOEHRINGER INGELHEIM INTPriority: Dec 24, 2004Filed: Aug 2, 2023Published: Nov 23, 2023
Est. expiryDec 24, 2024(expired)· nominal 20-yr term from priority
Inventors:John ParkGerald Juergen RothArmin HeckelNveed ChaudharyTrixi BrandlGeorg DahmannMatthias Grauert
A61K 31/4045A61K 31/404A61K 31/44A61K 31/445A61K 31/495A61K 31/496A61P 43/00A61K 31/4178A61K 31/454A61K 31/5377A61K 31/551A61K 45/06C07D 209/34C07D 401/12C07D 403/12C07D 295/155C07D 295/215C07D 471/04A61K 9/2866A61K 9/2018A61K 9/02A61K 9/0031A61K 9/10A61K 9/0095A61K 9/1623A61K 9/08A61K 9/0078A61K 9/0075A61K 47/10A61K 47/38A61K 9/0019
85
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as herein, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating idiopathic pulmonary fibrosis, comprising administering to a patient in need thereof a therapeutically effective amount of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenylmethylene]-6-methoxycarbonyl-2-indolinone, or a salt thereof. 
     
     
         2 . The method of  claim 1 , wherein 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenylmethylene]-6-methoxycarbonyl-2-indolinone is in the form of a monoethanesulfonate salt.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.